DNA in a pregnant woman's blood can reliably show whether her foetus has Down's syndrome, thus hugely reducing the need for invasive test procedures such as amniocentesis, research published on Tuesday said.Down's syndrome, a major developmental disorder also called trisomy 21, occurs in around one in every 800 live births.Pre-natal diagnosis mainly entails sampling fluid, drawn by a needle, from the amniotic sac enveloping the foetus. Another technique is called chorionic villus sampling, and entails taking a sample of placenta.
Technology is making it easier to monitor patients closely with completely non-invasive medical procedures that were once necessary. Pulse oximetry, a non-invasive method developed and commercialized in the U.S. in the late 1980s, is now widely used to monitor of the saturation of a patient's hemoglobin by placing sensors on a thin part of the patient's body, such as a finger or a earlobe.
A test designed to spot chromosome abnormalities in eggs could be a "revolution" in fertility, helping older women determine their chances of having an IVF baby, doctors said on Monday.But in developing the test, they added, worrying evidence emerged that in-vitro fertilisation (IVF) may boost the risk of a baby with Down's syndrome.
By The Swiss Trader:It is fortunate for all cancer patients and sufferers that innovations in treatment are evolving at a rapid pace. No longer must patients be subjected to invasive procedures and surgeries, nor are the only other viable options radiation and chemotherapy, which both leave the patient in a very weakened state. There are currently many companies vying for a place in the very large and complex cancer treatment space.